340 related articles for article (PubMed ID: 32744418)
1. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
[TBL] [Abstract][Full Text] [Related]
2. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Leiter LA; Bain SC; Bhatt DL; Buse JB; Mazer CD; Pratley RE; Rasmussen S; Ripa MS; Vrazic H; Verma S
Diabetes Obes Metab; 2020 Sep; 22(9):1690-1695. PubMed ID: 32372454
[TBL] [Abstract][Full Text] [Related]
3. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Verma S; Al-Omran M; Leiter LA; Mazer CD; Rasmussen S; Saevereid HA; Sejersten Ripa M; Bonaca MP
Diabetes Obes Metab; 2022 Jul; 24(7):1288-1299. PubMed ID: 35332654
[TBL] [Abstract][Full Text] [Related]
5. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.
Verma S; Bain SC; Monk Fries T; Mazer CD; Nauck MA; Pratley RE; Rasmussen S; Saevereid HA; Zinman B; Buse JB
Diabetes Obes Metab; 2019 Jul; 21(7):1745-1751. PubMed ID: 30851070
[TBL] [Abstract][Full Text] [Related]
6. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Shaman AM; Bain SC; Bakris GL; Buse JB; Idorn T; Mahaffey KW; Mann JFE; Nauck MA; Rasmussen S; Rossing P; Wolthers B; Zinman B; Perkovic V
Circulation; 2022 Feb; 145(8):575-585. PubMed ID: 34903039
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
Webb J; Mount J; von Arx LB; Rachman J; Spanopoulos D; Wood R; Tritton T; Massey O; Idris I
Diabetes Obes Metab; 2022 Feb; 24(2):289-295. PubMed ID: 34668637
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
13. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó R; Hernández C
Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
[TBL] [Abstract][Full Text] [Related]
14. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Kaul S
Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
17. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Husain M; Bain SC; Jeppesen OK; Lingvay I; Sørrig R; Treppendahl MB; Vilsbøll T
Diabetes Obes Metab; 2020 Mar; 22(3):442-451. PubMed ID: 31903692
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]